NCT02776059View on ClinicalTrials.gov

Pegfilgrastim in Patients With Alcoholic Hepatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 21, 2017

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2021

Conditions
Alcoholic Hepatitis
Interventions
DRUG

Standard of care + pegfiltrastim

prednisolone or pentoxifyline orally for 28 days + pegfilgrastim (Neulasta®) 6 mg in 0.6 mL SQ

DRUG

Standard of care

Oral prednisolone or pentoxifyline for 28 days only

Trial Locations (5)

87108

New Mexico VA Health Care System, Albuquerque

90089

LAC-USC Medical Center, Los Angeles

90502

Harbor-UCLA Medical Center, Torrance

92357

VA Loma Linda Healthcare System, Loma Linda

98022

VA Long Beach Healthcare System, Long Beach

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

Timothy Morgan, MD

OTHER

NCT02776059 - Pegfilgrastim in Patients With Alcoholic Hepatitis | Biotech Hunter | Biotech Hunter